Objective:To investigate the effect of volume-based procurement on the procurement and administration of insulin,and provide reference for rational use and the selection of therapeutic regime of insulin,the usage situation and development trend of insulin was analyzed in the hospital half a year before and after the volume-based procurement.Methods:The data of insulin administration was retrieved from HIS before(July to December 2021)and after(July to December 2022)the implementation of insulin volume-based procurement,which was used to analyze and count defined daily dose(DDD),DDDs,DDC,sorting ratio and the usage amount of insulin in the hospital according to the instructions for the limited daily dose of insulin and related insulin provided on the official website of World Health Organization.Results:Half a year after volume-based procurement,insulin usage amount increased by 21.20％compared with before,while the sales decreased by 47.69％.In addition,after volume-based procurement:the DDDs values of 14 products increased,in which insulin glulisine 3 mL:300 IU(Sanofi)and protamine zinc recombinant lysine insulin injection(25R)3 mL:300 IU(Lilly)were with larger increases(with a change range of ≥ 50％)of DDDs;the DDC value of all of insulin in the hospital decreased,in which 7 products decreased more than 50％and others decreased more than 30％;the products with sorting ratio ≥ 1 increased by 11 percent.Conclusion:The national policy of volume-based procurement contributes to form a reasonable drug price formation mechanism,and the decreases in drug costs improve the sustainability and compliance of patients with chronic diseases administrated with medicine,which meanwhile reduce the economic burden on medical insurance and patients greatly.Moreover,insulin glargine and insulin deglutinin become the growth points of insulin consumption in the hospital,while the consumption of isophane protamine recombinant human insulin decreases significantly,which should be adjusted in the declaration of insulin pre-procurement in the next year.Additionally,ascribed to the insufficient clinical awareness and misgiving of the efficacy and safety,the newly introduced varieties are with less usage,which requires the vigorous promotion by pharmacists in the future.
Volume-based purchaseInsulinDrug use frequencyAverage daily costDiabetes
NETL
NSTL
万方数据
